ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO442

Comprehensive Profiling of the Clinical Nephropathies in Participants of the H3Africa Kidney Disease Research Network Project Cohort Study

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Raji, Yemi R., University of Ibadan and University College Hospital, Ibadan, Oyo State, Nigeria, Ibadan, Nigeria
  • Ilori, Titilayo O., Emory University School of Medicine, Chandler, Arizona, United States
  • Kumar, Shikhar, The university of arizona, Tucson, Arizona, United States
  • Mamven, Manmak, University of Abuja, Abuja, Oyo, Nigeria
  • Parekh, Rulan S., The Hospital For Sick Children , Toronto, Ontario, Canada
  • Gbadegesin, Rasheed A., Duke University Medical Center, Durham, North Carolina, United States
  • Salako, Babatunde Lawal, University of Ibadan, Ibadan, Nigeria
  • Adu, Dwomoa, University of Ghana, Accra, Ghana
  • Ojo, Akinlolu O., University of Arizona Health Sciences, Tucson, Arizona, United States

Group or Team Name

  • H3Africa Kidney Disease Research Network

It is estimated that more than greater than 50 million African Blacks have Chronic Kidney Disease (CKD) due to clinically defined nephropathies. A significant fraction of these will progress to ESRD. Despite the high rate of CKD progression among individuals of African ancestry, the molecular and clinical factors underlying this high burden is not completely understood. The ongoing H3Africa Kidney Disease Cohort study aims to evaluate the independent contribution of risk variants in the APOL1 genes to the progression of clinically defined nephropathies among 3,000 African Blacks. This abstract described the baseline characteristics of the participants of the study


A longitudinal study of 3,000 African black with clinical defined nephropathies. It involves baseline and follow up visits. At the baseline, relevant clinical information was obtained while blood and urine specimens were collected for the assays. Biological specimens were processed, stored, packaged and shipped to the central repository for analysis. Information obtained from participants were demographics, contact information and medical history and blood was collected for DNA, RNA, whole blood, serum creatinine, full blood count and anthropometric measures. Where clinically indicated a kidney biopsy was performed and kidney tissue examined histologically.


A total of 2,192 participants were included in this analysis, and the clinical nephropathies include hypertensive nephropathy 1194 (54.5%), diabetic nephropathy 558(25.5%), sickle cell nephropathy 63(2.9%) and CKD of unknown aetiology 377(17.2%). The mean age among participants were 53.84±14.41, 58.92±11.46, 35.24 ±13.67 and 37.08 ±15.97years for hypertyensive, diabetic and sickle cell nephropathies and CKD of unknown aetiology respectively. Albumin-Creatinine Ratio was higher among participants with CKD of unknown aetiology (165.09±302.49mg/Mmol) and sickle cell nephropathy (109.13±111.18mg/mMol) compared to hypertensive nephropathy 62.68±184.32mg/mMol) and diabetic nephropathy (78.71± 144.61mg/mMol)


Hypertensive nephropathy, diabetic nephropathy and CKD of unknown aetiology are the leading clinically defined nephropathies among the sub-Saharan African population


  • NIDDK Support